HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 286/3/H1027    most recent 00630.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Nan, Y.-S. Articles by Ishikawa, N. Search for Related Content PubMed PubMed Citation Articles by Nan, Y.-S. Articles by Ishikawa, N.

Neuropeptide Y enhances permeability across a rat aortic endothelial cell monolayer

¹Department of Anesthesiology, Nagoya University School of Medicine, Nagoya 480-1195; and Departments of ²Pharmacology and ³Anesthesiology, Aichi Medical University School of Medicine, Aichi 480-1195, Japan

Submitted 3 July 2003 ; accepted in final form 22 October 2003

Previously, in vivo studies showed that neuropeptide Y (NPY) elevates vascular permeability in isolated lung perfusion preparations, possibly through binding to the NPY Y₃ receptor. The present study used monolayers in a double-chamber culture method under conditions of normoxia (5% CO₂-20% O₂-75% N₂) or hypoxia (5% CO₂-5% O₂-90% N₂) to test the hypothesis that NPY directly affects rat aortic endothelial cells (RAECs). RAECs were cultured on the base of the upper chamber, into which FITC-labeled albumin was introduced, and permeation into the lower chamber was measured. The RAEC monolayer was treated with 10^–8–3 x 10^–7 M NPY for 2 h in normoxia or hypoxia. In hypoxia, NPY concentration dependently increased the permeability of the RAEC monolayer, whereas in normoxia no significant change was observed. Peptide YY, NPY Y₁, and NPY Y₂ receptor agonists and NPY Y₁ receptor antagonist exerted no significant effects under hypoxic conditions. NPY-(18–36), an NPY Y₃ receptor antagonist, elicited an inhibitory action on the NPY-induced increase in monolayer permeability. Furthermore, neither N-monomethyl-L-arginine, a nitric oxide synthase inhibitor, the bradykinin B₂ receptor antagonist FK-3657, nor the vascular endothelial growth factor receptor-coupled tyrosine kinase inhibitor tyrphostin SU-1498, injected into the medium of the upper chamber, affected the NPY-induced permeability changes under hypoxic conditions. The results suggest that the NPY-induced increase in permeability across the RAEC monolayer is closely related to low O₂ tension, possibly mediated by direct action on the NPY Y₃ receptor expressed on the endothelial cell membrane. Furthermore, this NPY-induced increase is not likely due to nitric oxide, bradykinin, or vascular endothelial growth factor.

peptide YY; hypoxia

This article has been cited by other articles:

				Z.-Y. Chen, G.-G. Feng, K. Nishiwaki, Y. Shimada, Y. Fujiwara, T. Komatsu, and N. Ishikawa Possible roles of neuropeptide Y Y3-receptor subtype in rat aortic endothelial cell proliferation under hypoxia, and its specific signal transduction Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H959 - H967. [Abstract] [Full Text] [PDF]

				N. Kurimoto, Y.-S. Nan, Z.-Y. Chen, G.-G. Feng, T. Komatsu, N. Kandatsu, J. Ko, N. Kawai, and N. Ishikawa Effects of specific signal transduction inhibitors on increased permeability across rat endothelial monolayers induced by neuropeptide Y or VEGF Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H100 - H106. [Abstract] [Full Text] [PDF]